Publication:
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.

Simple item page
dc.contributor.authorRetamar, Pilar
dc.contributor.authorLópez-Cerero, Lorena
dc.contributor.authorMuniain, Miguel Angel
dc.contributor.authorPascual, Álvaro
dc.contributor.authorRodríguez-Baño, Jesús
dc.contributor.authoraffiliation[Retamar,P; López-Cerero,L; Muniain,MA; Pascual,A; Rodríguez-Baño,J] Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Muniain,MA; Rodríguez-Baño,J] Departamento de Medicina, Universidad de Sevilla, Sevilla, Spain. [Pascual,A] Departamento de Microbiología, Universidad de Sevilla, Sevilla, Spain.es
dc.contributor.funderThis study was funded by the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, and cofinanced by the European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), Fondo de Investigación Sanitaria (grants 070190, 10/02021, and 10/01955), and Junta de Andalucía (grants 0063/2006, 0048/2008, and CTS-5259)
dc.contributor.groupESBL-REIPI/GEIH Groupes
dc.date.accessioned2016-03-09T12:11:37Z
dc.date.available2016-03-09T12:11:37Z
dc.date.issued2013-07
dc.descriptionJournal Article; Research Support, Non-U.S. Gov't;es
dc.description.abstractWe investigated the impact of the piperacillin-tazobactam MIC in the outcome of 39 bloodstream infections due to extended-spectrum-β-lactamase-producing Escherichia coli. All 11 patients with urinary tract infections survived, irrespective of the MIC. For other sources, 30-day mortality was lower for isolates with a MIC of ≤ 2 mg/liter than for isolates with a higher MIC (0% versus 41.1%; P = 0.02).es
dc.description.versionYeses
dc.identifier.citationRetamar P, López-Cerero L, Muniain MA, Pascual Á, Rodríguez-Baño J, Gijón P, et al. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob. Agents Chemother. 2013; 57(7):3402-4es
dc.identifier.doi10.1128/AAC.00135-13
dc.identifier.essn1098-6596
dc.identifier.issn0066-4804
dc.identifier.pmcPMC3697383
dc.identifier.pmid23612190
dc.identifier.urihttp://hdl.handle.net/10668/2160
dc.journal.titleAntimicrobial agents and chemotherapy
dc.language.isoen
dc.publisherAmerican Society for Microbiologyes
dc.relation.publisherversionhttp://aac.asm.org/content/57/7/3402.abstractes
dc.rights.accessRightsopen access
dc.subjectAntibacterianoses
dc.subjectEstudios de cohorteses
dc.subjectQuimioterapia combinadaes
dc.subjectInfecciones por escherichia colies
dc.subjectPruebas de sensibilidad microbianaes
dc.subjectÁcido senicilánicoes
dc.subjectInfecciones urinariases
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agentses
dc.subject.meshMedical Subject Headings::Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Bacteremiaes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studieses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combinationes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitorses
dc.subject.meshMedical Subject Headings::Organisms::Bacteria::Proteobacteria::Gammaproteobacteria::Enterobacteriaceae::Escherichia::Escherichia colies
dc.subject.meshMedical Subject Headings::Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Enterobacteriaceae Infections::Escherichia coli Infectionses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Microbiological Techniques::Microbial Sensitivity Testses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Lactams::beta-Lactams::Penicillins::Penicillanic Acides
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Lactams::beta-Lactams::Penicillins::Penicillin G::Ampicillin::Piperacillines
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcomees
dc.subject.meshMedical Subject Headings::Diseases::Bacterial Infections and Mycoses::Infection::Urinary Tract Infectionses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Amidohydrolases::beta-Lactamaseses
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Agedes
dc.titleImpact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.es
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Retamar_ImpactMICPiperacillin-Tazobactam.pdf
Size:
321.56 KB
Format:
Adobe Portable Document Format
Description:
Artículo publicado
Download
Thumbnail Image
Name:
Retamar_ImpactMICPiperacillin_so1.pdf
Size:
14.87 KB
Format:
Adobe Portable Document Format
Description:
tablas
Download

Collections

SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía